4.6 Article

Cohort profile: the South African HIV Cancer Match (SAM) Study, a national population-based cohort

Journal

BMJ OPEN
Volume 12, Issue 4, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2021-053460

Keywords

HIV & AIDS; epidemiology; public health; epidemiology

Funding

  1. National Cancer Institute (NCI)
  2. National Institute of Allergy and Infectious Diseases of the National Institutes of Health [U01AI069924]
  3. National Institutes of Health (NIH) [U01AI069924--09]
  4. PEPFAR supplement
  5. Swiss National Science Foundation [320030_169967, 189498]
  6. U.S. CRDF Global [HIV_DAA3--16--62705--1]
  7. Swiss National Science Foundation (SNF) [320030_169967] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

The South African HIV Cancer Match (SAM) Study is a national cohort of people living with HIV, aiming to assess the spectrum and risk of cancer in PLWH to inform cancer prevention and control programmes in South Africa. The study includes over 5 million PLWH for the period 2004 to 2014, with a focus on enriching the research through record linkages with other laboratory data and socio-economic data to comprehensively study comorbidities among PLWH.
Purpose The South African HIV Cancer Match (SAM) Study is a national cohort of people living with HIV (PLWH). It was created using probabilistic record linkages of routine laboratory records of PLWH retrieved by National Health Laboratory Services (NHLS) and cancer data from the National Cancer Registry. The SAM Study aims to assess the spectrum and risk of cancer in PLWH in the context of the evolving South African HIV epidemic. The SAM Study's overarching goal is to inform cancer prevention and control programmes in PLWH in the era of antiretroviral treatment in South Africa. Participants PLWH (both adults and children) who accessed HIV care in public sector facilities and had HIV diagnostic or monitoring laboratory tests from NHLS. Findings to date The SAM cohort currently includes 5 248 648 PLWH for the period 2004 to 2014; 69% of these are women. The median age at cohort entry was 33.0 years (IQR: 26.2-40.9). The overall cancer incidence in males and females was 235.9 (95% CI: 231.5 to 240.5) and 183.7 (181.2-186.2) per 100 000 person-years, respectively. Using data from the SAM Study, we examined national cancer incidence in PLWH and the association of different cancers with immunodeficiency. Cancers with the highest incidence rates were Kaposi sarcoma, cervix, breast, non-Hodgkin's lymphoma and eye cancer. Future plans The SAM Study is a unique, evolving resource for research and surveillance of malignancies in PLWH. The SAM Study will be regularly updated. We plan to enrich the SAM Study through record linkages with other laboratory data within the NHLS (eg, tuberculosis, diabetes and lipid profile data), mortality data and socioeconomic data to facilitate comprehensive epidemiological research of comorbidities among PLWH.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available